Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of pegcetacoplan for geographic atrophy secondary to age-related macular degeneration
MOH_2021-08-31_010231Phase 3Not yet recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Jul 2021
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of pegcetacoplan in age-related macular degeneration (AMD) (2 arms), sponsored by Apellis Pharmaceuticals. Primary endpoint: Not specified. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
pegcetacoplan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on MOH_2021-08-31_010231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-31_010231.